Optimizing Dosing Strategies in CLL: Insights for Healthcare Providers

Optimizing Dosing Strategies in CLL: Insights for Healthcare Providers

Optimizing Dosing Strategies in CLL: Insights for Healthcare Providers from Patient Empowerment Network on Vimeo.

What can CLL healthcare professionals do to better understand novel therapy dosing? Expert Dr. Daniel Ermann from Huntsman Cancer Institute discusses how CLL treatment dosing typically begins and common situations when dose adjustments are made.

Download Resource Guide  | Descargar guía de recursos

See More from EPEP CLL

Related Resources:

Optimizing CLL Therapy: Strategies for Dose Escalation and Reduction

Optimizing CLL Therapy: Strategies for Dose Escalation and Reduction

Addressing Practice Gaps in CLL Therapy: Overcoming Barriers and Enhancing Patient Care

Addressing Practice Gaps in CLL Therapy: Overcoming Barriers and Enhancing Patient Care

How Can We Effectively Manage Dose Adjustments to Balance Efficacy and Toxicity in CLL?

How Can We Effectively Manage Dose Adjustments to Balance Efficacy and Toxicity in CLL?

Transcript:

Dr. Nicole Rochester:

How do CLL healthcare providers better understand dosing, particularly with the emergence of novel CLL therapies?

Dr. Daniel Ermann:

So I think nowadays, most of us in the CLL community, we’re really no longer using chemotherapy. We’re using, like Dr. Chang said, we’re sticking to these novel agents, BCL-2 inhibitors, BTK inhibitors in the frontline setting. All of these medications have been studied to the optimal dose in their respective trials.

And for the most part, we start every patient, except for the venetoclax (Venclexta) ramp-up, we start all patients at the optimal dose for what we think for them is the maximum tolerated dose in the studies, which is the dose seen in the FDA package inserts and the recommended starting dose.

So I think for most patients, generally we start at what dose that is recommended. And then the only time we really begin to dose-reduce is as Dr. Chang mentioned, if we’re seeing side effects or intolerance. So these are things that I always start looking at very early when I start patients on treatments. I check in with my patients within the first two weeks of them starting a BTK inhibitor. And then during the venetoclax ramp-up with BCL-2 inhibitors, I keep a very close eye on them.

So I think though these novel therapies are extremely effective at treating CLL, they do come with some toxicities. And it’s important to be aware of the toxicities, to keep an eye on the patients when you start them and know what the dose reductions are and how to effectively manage them.

Dr. Nicole Rochester:

Thank you, Dr. Ermann. And I just want to acknowledge and thank both of you for highlighting the importance of partnering with patients, particularly in an Empowering Providers to Empower Patients program. We understand that this is a partnership between the healthcare providers and the patients. And so I appreciate both of you really highlighting the importance of engaging with the patients and then making necessary adjustments. 


Share Your Feedback